Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)

被引：0
|
作者：
Gregori, Joaquin Gavila
Miranda, Elena Lopez
Escriva-de-Romani, Santiago
Rodriguez, Begona Jimenez
Novoa, Silvia Antolin
Morales, Luis Fernandez
Calvo, Elena Galve
Cortijo, Lucia Gonzalez
Martorell, Antonia Perello
Ruiz, Julian Lagunar
Santiago, Santiago Gonzalez
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT1-12-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-12-09
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer
    Ziegengeist, Julia L.
    Tan, Antoinette R.
    CLINICAL BREAST CANCER, 2025, 25 (02) : e124 - e132
  • [2] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach
    DuMond, Barbara
    Patel, Vidhi
    Gross, Anne
    Fung, Anita
    Weber, Susan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1214 - 1221
  • [3] FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER (HER2+BC) PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS
    Bellone, M.
    Pradelli, L.
    Sanfilippo, A.
    Caputo, A.
    Manevy, M.
    Zerilli, A.
    VALUE IN HEALTH, 2022, 25 (01) : S109 - S109
  • [4] Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer
    Swain, Sandra M.
    Tan, Antoinette R.
    Gianni, Luca
    Kuemmel, Sherko
    Dang, Chau T.
    Schneeweiss, Andreas
    O'Shaughnessy, Joyce
    Liu, Haiying
    Aguila, Christian
    Heeson, Sarah
    Macharia, Harrison
    Yang, Ke
    Restuccia, Eleonora
    Loibl, Sibylle
    EUROPEAN JOURNAL OF CANCER, 2023, 178 : 70 - 81
  • [5] Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
    Bei Wang
    Rong Deng
    Stefanie Hennig
    Tanja Badovinac Crnjevic
    Monika Kaewphluk
    Matts Kågedal
    Angelica L. Quartino
    Sandhya Girish
    Chunze Li
    Whitney P. Kirschbrown
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 499 - 512
  • [6] Cost minimization analysis of treatments for metastatic HER2-positive breast cancer in Peru: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injections
    Figallo, Miguel
    Delgado, Maria F.
    Gonzalez, Mauricio
    Arenas, Adrian
    PLOS ONE, 2024, 19 (11):
  • [7] Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
    Bei Wang
    Rong Deng
    Stefanie Hennig
    Tanja Badovinac Crnjevic
    Monika Kaewphluk
    Matts Kågedal
    Angelica L. Quartino
    Sandhya Girish
    Chunze Li
    Whitney P. Kirschbrown
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 571 - 572
  • [8] Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
    Wang, Bei
    Deng, Rong
    Hennig, Stefanie
    Badovinac Crnjevic, Tanja
    Kaewphluk, Monika
    Kagedal, Matts
    Quartino, Angelica L.
    Girish, Sandhya
    Li, Chunze
    Kirschbrown, Whitney P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (03) : 499 - 512
  • [9] A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer
    De Cock, Erwin
    Pivot, Xavier
    Hauser, Nik
    Verma, Sunil
    Kritikou, Persefoni
    Millar, Douglas
    Knoop, Ann
    CANCER MEDICINE, 2016, 5 (03): : 389 - 397
  • [10] Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
    O'Shaughnessy, Joyce
    Sousa, Susana
    Cruz, Josefina
    Fallowfield, Lesley
    Auvinen, Paivi
    Pulido, Catarina
    Cvetanovic, Ana
    Wilks, Sharon
    Ribeiro, Leonor
    Burotto, Mauricio
    Klingbiel, Dirk
    Messeri, Dimitri
    Alexandrou, Ari
    Trask, Peter
    Fredriksson, Judy
    Machackova, Zuzana
    Stamatovic, Ljiljana
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 223 - 232
12345